Supportive Care in Cancer

, Volume 20, Issue 7, pp 1471–1478

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

  • Paul J. Hesketh
  • Oliver Wright
  • Gerardo Rosati
  • Mark Russo
  • Jeremey Levin
  • Stephen Lane
  • Vladimir Moiseyenko
  • Pierre Dube
  • Mikhail Kopp
  • Anatoly Makhson
Original Article



The primary objective was to determine if a single dose of casopitant 90 mg added to ondansetron and dexamethasone would improve the control of chemotherapy-induced nausea and vomiting (CINV) over 0–120 h following initiation of oxaliplatin-based moderately emetic chemotherapy (MEC) compared to ondansetron and dexamethasone alone.


Patients with colorectal cancer received either casopitant or placebo intravenously (IV) added to ondansetron 8 mg bid oral on study days 1 to 3 and one dose of dexamethasone 8 mg IV given prior to starting the oxaliplatin on day 1. The primary endpoint was the percentage of subjects achieving complete response (CR; no vomiting/retching or use of rescue medication) during 120 h after initiation of chemotherapy in cycle 1.


No difference in the rate of CR was noted in the casopitant group compared to the placebo group for the overall (placebo 85%, casopitant 86%, p = 0.7273), acute (placebo 96%, casopitant 97%), or delayed phases (placebo 85%, casopitant 86%). The average area under curve (0–) of casopitant after a single 90-mg IV dose was 8,390 ng h/mL. At 24 h after casopitant 90-mg IV dosing, the plasma casopitant concentration was 24% lower than the values noted in prior studies with 150 mg oral administration, and the plasma exposure of the major metabolite (GSK525060) was 18% lower.


Addition of single-dose casopitant 90 mg IV did not improve the control of CINV at any time during 120 h following initiation of oxaliplatin-based MEC. Excellent control of CINV was achieved in this study population with the combination of ondansetron and dexamethasone alone.


CINV Pharmacokinetics Acute nausea and vomiting Delayed nausea and vomiting MEC 


  1. 1.
    de Boer-Dennert M, de Wit R, Schmitz PI, Djontono J, van Beurden V, Stoter G, Verweij J (1997) Patient perceptions of the side effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76(8):1055–1061PubMedCrossRefGoogle Scholar
  2. 2.
    Kris MG, Gralla RJ, Clark RA, Tyson LB, O’Connell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3(10):1379–1384PubMedGoogle Scholar
  3. 3.
    Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD (1996) Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 78(10):2193–2198PubMedCrossRefGoogle Scholar
  4. 4.
    Hesketh PJ (2008) Chemotherapy-induced nausea and vomiting. N Engl J Med 358(23):2482–2494PubMedCrossRefGoogle Scholar
  5. 5.
    Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103–109PubMedGoogle Scholar
  6. 6.
    Grunberg SM, Osoba D, Hesketh PJ, Gralla RJ, Borjeson S, Rapoport BL, du Bois A, Tonato M (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicityan update. Support Care Cancer 13(2):80–84PubMedCrossRefGoogle Scholar
  7. 7.
    Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112–4119PubMedCrossRefGoogle Scholar
  8. 8.
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098PubMedCrossRefGoogle Scholar
  9. 9.
    American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24(18):2932–2947PubMedCrossRefGoogle Scholar
  10. 10.
    Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, Lopez-Vega JM (1990) The natural course of emesis after carboplatin treatment. Acta Oncol 29(5):593–595PubMedCrossRefGoogle Scholar
  11. 11.
    du Bois A, Vach W, Cramer-Giraud U, Thomssen C, Glaubitz M, Fiola M (1995) Pattern of carboplatin-induced emesis. The German Ondansetron Study Group. Anti-Cancer Drugs 6(5):645–651PubMedCrossRefGoogle Scholar
  12. 12.
    Sharif S, O’Connell MJ, Yothers G, Lopa S, Wolmark N (2008) FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer. Cancer Invest 26(9):956–963PubMedCrossRefGoogle Scholar
  13. 13.
    Zhuang L, Bai J, Huang H, Tang C, Yang J, Zhou B, Gong Y, Duanmu Z, Chen J (2010) Meta-analysis of chemotherapy with irinotecan or oxaliplatin-involved regimen for untreated metastatic advanced colorectal cancer. Oncol Res 18(9):437–444PubMedCrossRefGoogle Scholar
  14. 14.
    Mathé G, Kidani Y, Triana K, Brienza S, Ribaud P, Goldschmidt E, Ecstein E, Despax R, Musset M, Misset JL (1986) A phase I trial of trans-1-diaminocyclohexane oxalato-platinum (l-OHP). Biomed Pharmacother 40(10):372–376PubMedGoogle Scholar
  15. 15.
    Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25(4):299–303PubMedCrossRefGoogle Scholar
  16. 16.
    Bécouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-André G, Rougier P (1998) Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16(8):2739–2744PubMedGoogle Scholar
  17. 17.
    Díaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortés-Funes H, de Braud F, Boni C, Benavides M, Dallavalle G, Homerin M (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol 9(1):105–108PubMedCrossRefGoogle Scholar
  18. 18.
    Arpornwirat W, Albert I, Hansen VL, Levin J, Bandekar RR, Grunberg SM (2009) Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. Cancer 115(24):5807–5816PubMedCrossRefGoogle Scholar
  19. 19.
    Hesketh PJ, Sanz-Altamira P, Bushey J, et al. Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy. Poster presented at the 2008 ASCO Annual Meeting; June 2008; Chicago, ILGoogle Scholar
  20. 20.
    Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumour types: a randomized, double-blind study. Support Care Cancer 18(4):423–431PubMedCrossRefGoogle Scholar
  21. 21.
    Herrstedt J, Apornwirat W, Shaharyar A, Aziz Z, Roila F, Van Belle S, Russo MW, Levin J, Ranganathan S, Guckert M, Grunberg SM (2009) Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 27(32):5363–5369PubMedCrossRefGoogle Scholar
  22. 22.
    Grunberg SM, Rolski J, Strausz J, Aziz Z, Lane S, Russo MW, Wissel P, Guckert M, Wright O, Herrstedt J (2009) Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(6):549–558PubMedCrossRefGoogle Scholar
  23. 23.
    Martin AR, Carides AD, Pearson JD, Horgan K, Elmer M, Schmidt C, Cai B, Chawla SP, Grunberg SM (2003) Functional relevance of anti-emetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. Eur J Cancer 39(10):1395–1401PubMedCrossRefGoogle Scholar
  24. 24.
    Melzack R, Rosberger Z, Hollingsworth ML, Thirlwell M (1985) New approaches to measuring nausea. CMAJ 133(8):755–758, 761PubMedGoogle Scholar
  25. 25.
    Martin AR, Cai B, Pearson J et al (2001) Patient-assessed impact of chemotherapy-induced nausea on daily life: how much is too much? Oncol Nurs Forum 28:338Google Scholar
  26. 26.
    Martin AR, Pearson J, Cai B et al (2002) Chemotherapy-induced nausea: VAS ratings <25 mm were predictive of patient reported outcomes. Proc Am Soc Clin Oncol 21:2918Google Scholar
  27. 27.
    Roila F, Rolski J, Ramlau R et al (2009) Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol 20:1867–1873PubMedCrossRefGoogle Scholar
  28. 28.
    Warr D, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Paul J. Hesketh
    • 1
  • Oliver Wright
    • 2
  • Gerardo Rosati
    • 3
  • Mark Russo
    • 2
  • Jeremey Levin
    • 2
  • Stephen Lane
    • 2
  • Vladimir Moiseyenko
    • 4
  • Pierre Dube
    • 5
  • Mikhail Kopp
    • 6
  • Anatoly Makhson
    • 7
  1. 1.Department of Hematology and OncologyLahey Clinic Medical CenterBurlingtonUSA
  2. 2.GSK Research and DevelopmentCollegevilleUSA
  3. 3.Medical Oncology UnitS. Carlo HospitalPotenzaItaly
  4. 4.Petrov Research Institute of OncologySaint PetersburgRussia
  5. 5.Hôpital Maisonneuve-RosemontUniversité de MontréalMontréalCanada
  6. 6.Samara Regional Oncology CenterSamaraRussian Federation
  7. 7.Stavropol Regional Oncology CenterStavropolRussian Federation

Personalised recommendations